Amphastar Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $183.90M | $0.67 | $0.91 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $171.20M | $0.14 | $0.42 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | During market hours | $183.10M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $191.80M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $174.40M | $0.64 | $0.85 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $170.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | $186.50M | $0.74 | $0.92 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $191.20M | $0.78 | $0.96 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | During market hours | – | – | – |
Press releases
Announcements Amphastar Pharmaceuticals filed with the SEC
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 20 24
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 24
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 24
Results of operations · EX-99.1 to Form 8-K
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 23
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 23
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Material agreement · Acquisition or disposition completed · New financial obligation · Other events · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 202 3
Results of operations · EX-99.1 to Form 8-K
For Release: April 24, 2023 @ 6:45 a.m. ET
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 22
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 22
Results of operations · EX-99.1 to Form 8-K
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 202 2
Results of operations · EX-99.1 to Form 8-K